FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Grace Dy

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Grace K Dy
The role of focal adhesion kinase in lung cancer.
Grace K Dy; Alan P Lyss; Sumithra J Mandrekar; Jeffrey P Meyers; Julian R Molina; Garth D Nelson; Helen J Ross; Steven E Schild; Philip J Stella; Araba A Adjei; Rafat H Ansari; Alex A. Adjei
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Thanyanan Reungwetwattana; Nicholas F Reuter; Kendrith M Rowland; Steven E Schild; Katie Allen-Ziegler; Grace K Dy; James R Jett; Ronnie F Luyun; Sumithra J Mandrekar; Randolph S Marks; Julian R Molina; Alex A. Adjei
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Grace Dy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Grace K Dy
The role of focal adhesion kinase in lung cancer.
Anti-cancer agents in medicinal chemistry 2013;13(4):581-3.
2013: Grace K Dy; Alan P Lyss; Sumithra J Mandrekar; Jeffrey P Meyers; Julian R Molina; Garth D Nelson; Helen J Ross; Steven E Schild; Philip J Stella; Araba A Adjei; Rafat H Ansari; Alex A. Adjei
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(1):79-88.
2012: Thanyanan Reungwetwattana; Nicholas F Reuter; Kendrith M Rowland; Steven E Schild; Katie Allen-Ziegler; Grace K Dy; James R Jett; Ronnie F Luyun; Sumithra J Mandrekar; Randolph S Marks; Julian R Molina; Alex A. Adjei
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(5):919-22.
2008: Bret B Friday; Chunrong Yu; Grace K Dy; Paul D Smith; Liang Wang; Stephen N Thibodeau; Alex A. Adjei
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Cancer research 2008;68(15):6145-53.
2007: Grace K Dy; James E Krook; Erin M Green; Daniel J Sargent; Thierry Delaunoit; Roscoe F Morton; Charlie S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Barbara A Pockaj; Robert P Sticca; Steven R Alberts; Henry C Pitot; Richard M Goldberg
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3469-74.
2006: Grace K Dy; James R Jett; Francois J Geoffroy; Keith D Krewer; Henry D Tazelaar; Matthew Maurer; Kendrith M Rowland; James A Mailliard; James E Krook; Shaker R Dakhil; Leila Kutteh; John Kugler; Donald B Wender
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(3):211-7.
2005: Grace K Dy; Sumithra J Mandrekar; Prema P Peethambaram; Scott H Okuno; Gary C Croghan; Lorelei J Hanson; Alfred F Furth; Alex A. Adjei
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2005;56(6):623-8.
2005: Grace K Dy; A A Miller; Sumithra J Mandrekar; M-C Aubry; R M Langdon; Roscoe F Morton; S E Schild; James R Jett; Alex A. Adjei
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1811-6.
2005: Grace K Dy; Ajit Suri; Joel M Reid; Jeff A Sloan; Henry C Pitot; Steven R Alberts; Richard M Goldberg; Pamela J Atherton; Lorelei J Hanson; Patrick A Burch; Joseph Rubin; Charles Erlichman; Alex A. Adjei
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(6):522-30.
2005: Grace K Dy; James P Thomas; George Wilding; Laura M Bruzek; Sumithra J Mandrekar; Charles Erlichman; Dona Alberti; Kim Binger; Henry C Pitot; Steven R Alberts; Lorelei J Hanson; Rebecca Marnocha; Kendra Tutsch; Scott H Kaufmann; Alex A. Adjei
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3410-6.
2005: Grace K Dy; Laura M Bruzek; Gary A Croghan; Sumithra J Mandrekar; Charles Erlichman; Prema P Peethambaram; Henry C Pitot; Lorelei J Hanson; Joel M Reid; Alfred F Furth; Shinta Cheng; Robert E Martell; Scott H Kaufmann; Alex A. Adjei
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1877-83.
2005: Grace K Dy; Alex A. Adjei
Obstacles and opportunities in the clinical development of targeted therapeutics.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 2005;63():19-41.
2004: Grace K Dy; Lishan Bekele; Lorelei J Hanson; Alfred F Furth; Sumithra J Mandrekar; Jeff A Sloan; Alex A. Adjei
Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4810-5.
2003: Alex A. Adjei; Grace K Dy; Charles Erlichman; Joel M Reid; Jeff A Sloan; Henry C Pitot; Steven R Alberts; Richard M Goldberg; Lorelei J Hanson; Pamela J Atherton; Tanya Watanabe; Richard S Geary; Jon T Holmlund; F Andrew Dorr
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):115-23.
2002: P Haluska; Grace K Dy; Alex A. Adjei
Farnesyl transferase inhibitors as anticancer agents.
European journal of cancer (Oxford, England : 1990) 2002;38(13):1685-700.
2001: Grace K Dy; P Haluska; Alex A. Adjei
Novel pharmacological agents in clinical development for solid tumours.
Expert opinion on investigational drugs 2001;10(12):2059-88.